$2.76
arrow_drop_down2.47%Key Stats | |
---|---|
Open | $2.96 |
Prev. Close | $2.83 |
EPS | -9.30 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $16.88M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 2.67 | 2.96 |
52 Week Range | 2.07 | 58.20 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -9.30 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation